Valneva SE (VALN)
NASDAQ: VALN · IEX Real-Time Price · USD
8.38
+0.10 (1.21%)
Jun 12, 2024, 4:00 PM EDT - Market closed

Company Description

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.

It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally.

Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine.

The company was founded in 1998 and is based in Saint-Herblain, France.

Valneva SE
Valneva SE logo
Country France
Founded 2012
IPO Date May 6, 2021
Industry Biotechnology
Sector Healthcare
Employees 676
CEO Thomas Lingelbach

Contact Details

Address:
6, Rue Alain Bombard
Saint-herblain, I0 44800
France
Phone 33 2 28 07 37 10
Website valneva.com

Stock Details

Ticker Symbol VALN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $26.41
CIK Code 0001836564
CUSIP Number 92025Y103
ISIN Number US92025Y1038
SIC Code 2836

Key Executives

Name Position
Thomas Lingelbach President, Chief Executive Officer and Director
Peter Buhler Chief Financial Officer
Frederic Jacotot Vice President of Legal and IP, General Counsel, and Corporate Secretary
Franck Grimaud MBA Chief Business Officer
Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer
Dipal Patel Chief Commercial Officer
Vincent Dequenne Chief Operating Officer
Joshua Drumm Ph.D. Vice President of Investor Relations
Laetitia Bachelot-Fontaine Vice President of Global Communications and European Investor Relations
Petra Pesendorfer Chief People Officer

Latest SEC Filings

Date Type Title
Jun 5, 2024 6-K Report of foreign issuer
Jun 4, 2024 6-K Report of foreign issuer
Jun 3, 2024 6-K Report of foreign issuer
May 31, 2024 6-K Report of foreign issuer
May 21, 2024 6-K Report of foreign issuer
May 13, 2024 6-K Report of foreign issuer
May 7, 2024 6-K Report of foreign issuer
Mar 26, 2024 6-K Report of foreign issuer
Mar 22, 2024 20-F Annual and transition report of foreign private issuers
Mar 22, 2024 6-K Report of foreign issuer